Literature DB >> 7977878

Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia.

S P Roose1, A H Glassman, E Attia, S Woodring.   

Abstract

OBJECTIVE: The popularity of selective serotonin reuptake inhibitors stems from their apparent efficacy for numerous disorders and their favorable side effect profile. However, several studies have suggested that selective serotonin reuptake inhibitors may be relatively ineffective for treating melancholia. The objective of this study was to compare the responses to fluoxetine and nortriptyline of older patients with both severe depression and heart disease.
METHOD: The outcome of 22 hospitalized patients with unipolar depression and heart disease who were treated with fluoxetine was compared to the outcome of 42 comparable patients treated with nortriptyline. The average age of the fluoxetine group was 73 years, and their mean pretreatment score on the Hamilton Depression Rating Scale was 26; the average age of the nortriptyline group was 70, and their mean pretreatment Hamilton score was 28.
RESULTS: Of the 42 nortriptyline-treated patients, 28 were responders, six were nonresponders, and eight dropped out. The intent-to-treat response rate was 67% (28 of 42), and the response rate of the melancholic patients who completed the nortriptyline trial was 83% (20 of 24). Of the 22 fluoxetine-treated patients, five were responders, 13 were nonresponders, and four dropped out. The intent-to-treat response rate was 23% (five of 22), and the response rate of the melancholic patients who completed the fluoxetine trial was 10% (one of 10).
CONCLUSIONS: Fluoxetine appears to be significantly less effective than nortriptyline for treating hospitalized elderly patients with unipolar major affective disorder, especially those with the melancholic subtype and concurrent cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977878     DOI: 10.1176/ajp.151.12.1735

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  28 in total

1.  Antidepressants for old people. GPs should become familiar with one or two antidepressants from each class.

Authors:  R C Baldwin
Journal:  BMJ       Date:  1999-09-25

Review 2.  Effects of medications on cerebral blood flow in late-life depression.

Authors:  Mitchell S Nobler; Kristian R Olvet; Harold A Sackeim
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

Review 3.  Design of clinical trials of antidepressants: should a placebo control arm be included?

Authors:  J Fritze; H J Möller
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients.

Authors:  Walter W van den Broek; Tom K Birkenhäger; Paul G H Mulder; Jan A Bruijn; Peter Moleman
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

5.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

Review 6.  Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.

Authors:  R J Goldberg
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 7.  Depression and myocardial infarction. Implications for medical prognosis and options for treatment.

Authors:  T J Cleophas
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 8.  Pharmacoeconomic evaluation of antidepressants : a critical appraisal of methods.

Authors:  Sheikh Usman Iqbal; Mark Prashker
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 9.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

Review 10.  Severe depression: is there a best approach?

Authors:  S B Sonawalla; M Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.